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ABSTRACT 
Ghrelin is a 28-amino-acid peptide that is the endogenous ligand for the 
pituitary growth hormone secretagogue receptor (GHS-R). Ghrelin is mainly 
produced from the stomach, but it is also expressed by various other tissues 
including the central nervous system under normal conditions. Physiologically, 
ghrelin regulates appetite, gut motility, and GH release from the anterior pituitary, 
as well as cardiovascular and immune systems. Recent studies also indicate that 
ghrelin and the GHS-R may play an important autocrine/paracrine role in 
neoplastic conditions. In order to clarify the role of ghrelin/GHS-R in gliomas, the 
present study assessed the expression of ghrelin and its functional receptor, 
GHS-R1a, in 39 glioblastomas (GBs), 13 anaplastic astrocytomas (AAs), and 11 
diffuse astrocytomas (DAs) using immunohistochemical analyses. 
Immunohistochemical staining was evaluated as follows: no staining; 1+, 0-10% 
positive cells; 2+, 10-50% positive cells; 3+, >50% positive cells. Ghrelin 
expression was detected in 52 of 63 cases of which 38, 13, and 1 were scored as 3+, 
2+, and 1+, respectively. GHS-R1a expression was detected in 45 of 63 cases of 
which 29, 15, and 1 were scored as 3+, 2+, and 1+, respectively. Ghrelin 
immunoreactivity was observed in 38 of 39 GBs, 12 of 13 AAs, and 2 of 11 DAs. 
GHS-R1a immunoreactivity was observed in 39 of 39 GBs, 5 of 13 AAs, and 1 of 
11 DAs. AAs and GBs showed moderate or strong immunostaining of 
ghrelin/GHS-R1a in the tumor cells and in proliferating microvessels. 
Patients were classified into lower to moderate-score, and high-score 
ghrelin/GHS-R categories according to the principal component and cluster 
analyses. Multivariate analysis of overall survival indicated that there was a 
significant difference (p=0.0001) in the survival rate between these two groups. 
The combined results indicated that expression of the ghrelin/GHS-R1a axis 
increases the growth of AAs and GBs through an autocrine/paracrine mechanism. 
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INTRODUCTION 
Kojima et al. identified ghrelin, a 28-amino acid peptide secreted by the 
stomach, as the endogenous ligand for the pituitary growth hormone secretagogue 
receptor (GHS-R).1,2 The organ expressing the highest amount of ghrelin is the 
stomach, where it is synthesized by and secreted from an endocrine cell in the 
submucosal layer of the stomach.1-3 However, ghrelin expression is not limited to 
the gastrointestinal tract, and ghrelin is distributed throughout the entire body, 
including the central nervous system. 1-4 GHS-R is a transmembrane G 
protein-coupled receptor for ghrelin and is also expressed in various organs, 
including in brain regions. 1,2 In addition to the regulation of GH secretion, the 
ghrelin/ GHS-R axis has many other functions, including the regulation of appetite 
and gut motility and of growth hormone release from the anterior pituitary and also 
plays roles in the cardiovascular and immune systems. 1-3 The discovery of ghrelin 
is a typical instance of reverse pharmacology because GHS-R was identified 
before its ligand, ghrelin. 5,6 Different isoforms of GHS-Rs have been cloned that 
are named GHS-R1a and GHS-R1b. GHS-R 1a encodes a full-length biologically 
active receptor; however, the GHS-R1b encodes a truncated receptor that is widely 
expressed throughout the entire body. 5-7 
Recent studies have indicated that ghrelin is highly expressed in various tumor 
tissues in which GHS-R is expressed along with ghrelin. 5-14 Accordingly, the 
possibility of an autocrine/paracrine role of ghrelin/GHS-R signaling in the 
regulation of cancer cell proliferation has aroused much interest. Regarding 
astrocytic tumors, Dixit et al. reported that ghrelin, acting via the functional 
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GHS-R 1a, increased intracellular calcium mobilization and led to membrane 
ruffling, which resulted in high motility and invasion of astrocytoma cells. 13 In 
addition, in an in vitro study, Chen et al. reported that ghrelin induced cell 
migration through a GHS-R, CaMKII, AMPK, and NF-κB signaling pathway in 
glioma cells. 14 To the best of our knowledge, however, immunohistochemical 
analysis of the specific localization of ghrelin/GHS-R1a expression in astrocytic 
tumors, particularly in glioblastomas (GBs), has not yet been studied. In the 
present study, therefore, we addressed the expression pattern of ghrelin/GHS-R1a 
in specimens of GBs and other astrocytic tumors and the correlation between 
ghrelin/GHS-R axis expression and patient prognosis, in order to clarify the role of 
ghrelin/GHS-R in the tumorigenesis of gliomas, particularly of GBs. 
 
MATERIALS and METHODS 
Cases 
Surgical tissue samples (n=63) from 63 patients with astrocytic tumors were 
analyzed in the present study. These astrocytic tumors consisted of 39 GBs, 13 
anaplastic astrocytomas (AAs), and 11 diffuse astrocytomas (DAs). All tumor 
specimens were retrieved from the archives of Kurume University and its 
affiliated hospitals between 2000 and 2012. Clinical information for the 63 
patients was also retrieved from these archives. This study was carried out in 
accordance with the principles of the Helsinki Declaration and was approved by 
the ethics committee of our institution. Tissue samples were fixed in 10% buffered 
formalin, embedded in paraffin, and processed using conventional histological and 
immunohistochemical methods. Sections (5 m) were stained with hematoxylin 
and eosin (HE) for histological evaluation. The remaining serial unstained 
sections were used for immunohistochemistry. All specimens were histologically 
diagnosed according to the World Health Organization criteria for tumours of the 
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central nervous system. 15 Immunohistochemical studies were performed on 
paraffin sections following heat-induced antigen retrieval, staining with the 
appropriate antibodies and signal detection with immunoperoxidase methods 
(ChemMate ENVISION kit/HRP(DAB), DakoCytomation) using an autostainer 
(Dako autostainer universal staining system). Primary antibodies were directed 
toward Ghrelin (dilution 1:200; AbD serotec, Oxford, UK), GHS-R1a (dilution 
1:400; Santa Cruz Biotechnology Inc., Santa Cruz, USA), endoglin (CD105, 
dilution 1:50; Novocastra, Newcastle, UK), and Ki-67 (MIB-1, dilution 
1:100;immunotech, Marseille, France). The MIB-1 labeling index was the 
percentage of nuclear area stained in areas of maximum labeling. The 
immunohistochemical studies were evaluated as follows; no staining; 1+, 0-10% 
positive cells ; 2+, 10-50% positive cells; 3+, >50% positive cells. The 
immunohistochemical evaluation was performed by two observers (Y.O and Y.S.) 
in independent readings. Cases that varied significantly between readers were 
re-evaluated in order to arrive at a consensus. 
 
Fluorescence immunohistochemical staining 
In two cases of glioblastoma, fluorescent double immunostaining of ghrelin 
and GHS-R1a expression, of endoglin (CD105) and GHS-R1a expression, and of 
Ki-67 and GHS-R1a expression in GB tissues was performed. Co-staining was 
performed by staining GHS-R1a with rabbit anti-GHS-R1a antibodies, and by 
co-staining for ghrelin, endoglin (CD105) or Ki-67 with with mouse anti-ghrelin, 
anti-endoglin (CD105) or anti-Ki-67 (MIB-1) antibodies, respectively, followed 
by their respective staining by addition of anti-rabbit IgG-Texas Red (TR) 
(sc-2780, Santa Cruz Biotechnology) and anti-mouse IgG-Alexa488 (Life 
Technologies, CA, USA) as appropriate. Fluorescence was analyzed using a 
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fluorescent microscope (BX51FL, Olympus, Tokyo, Japan) and a CCD camera 
(DP71, Olympus, Tokyo, Japan). 
Statistical analysis 
To gain a better understanding of the correlation between expression of 
ghrelin/GHS-R in GBs and patient prognosis, statistical analyses among the 
relevant groups were performed using SAS 9.4 (SAS Institute, Cary, NC, USA). 
Survival rates were computed using the Kaplan-Meier method. Patients were 
censored on loss-to-follow-up at the time of analysis. When multivariate analysis 
of overall survival was studied, principal component analysis was conducted to 
assess patterns in ghrelin, GHS-R1a expression, and patient age. 16 In addition, 
cluster analysis was done for new indices. 17 A log-rank test and a Cox 
proportional hazards regression model were used for univariate and multivariate 
analyses of overall survival, respectively. In addition, to determine the 
relationship between the levels of expression of Ghrelin/ GHSR-1a and the MIB-1 
labelling index, we performed a Kendall tau rank correlation test between Ghrelin 
and the MIB-1 labelling index in gliomas, or between GHSR-1a and the MIB-1 
labelling index in gliomas using SAS 9.4 (SAS Institute, Cary, NC, USA). 
Statistical significance was set at the level of P<0.01. 
 
RESULTS 
The patient data and immunohistochemical findings of the 63 cases studied are 
summarized in Table 1 and Table 2. All patients with GBs and AAs had received 
radiation therapy and chemotherapy. All patients with ASs had received radiation 
therapy. The staining intensity of tumor cells was correlated with the percentage of 
tumor cells immunostained for both ghrelin and GHS-R1a expression. Ghrelin 
expression was detected in 52 of 63 cases of which 38, 13, and 1 cases were scored 
as a staining intensity of 3+, 2+, and 1+, respectively. GHS-R1a expression was 
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detected in 45 of 63 cases of which 29, 15, and 1 cases were scored as a staining 
intensity of 3+, 2+, and 1+, respectively. Ghrelin immunoreactivity was observed 
in 38 of 39 GBs, 12 of 13 AAs, and 2 of 11 DAs. GHS-R1a immunoreactivity was 
observed in 39 of 39 GBs, 5 of 13 AAs, and 1 of 11 DAs.  
In GBs, ghrelin expression was detected in 38 of 39 cases of which 29 and  9 
cases were scored as a staining intensity of 3+ and 2+, respectively. Cases that 
were scored as 3+ and 2+ showed strong immunostaining either of the 
pseudopalisading cells or of proliferating multilayered microvessels (Fig. 1a, 1b). 
GHS-R1a expression was detected in 39 of 39 cases of which 26 and 13 cases were 
scored as a staining intensity of 3+ and 2+, respectively. Cases that were scored as 
3+ and 2+ also showed strong immunostaining either of the pseudopalisading cells 
or of proliferating multilayered microvessels (Fig. 1c,1d). 
In AAs, ghrelin expression was detected in 12 of 13 cases of which 9 and 3 
cases were scored as a staining intensity of 3+ and 2+, respectively. Cases that 
were scored as 3+ and 2+ showed strong immunostaining in proliferating 
microvessels and their surrounding tumor cells (Fig. 2a). GHS-R1a expression in 
AAs was detected in 5 of 13 cases of which 3 and 2 cases were scored as a staining 
intensity of 3+ and 2+, respectively. Cases that were scored as 3+ and 2+ also 
showed strong immunostaining of proliferating microvessels and their 
surrounding tumor cells (Fig. 2b). 
In DAs, ghrelin expression was detected in 2 of 11 cases, and these 2 cases 
were each scored as a staining intensity of 1+ and 2+, respectively. The cases that 
were scored as 1+ showed weak immunostaining in tumor cells and negative 
immunostaining in proliferating microvessels (Fig. 2c). GHS-R1a expression in 
DAs was detected in 1 of 11 cases and this case was scored as a staining intensity 
of 1+. Representative immunohistochemical staining of GHS-R1a in DA tissue 
showed no GHS-R1a immunostaining of tumor cells or of endothelial cells of 
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proliferating microvessels (Fig. 2d). In summary, strong expression of 
ghrelin/GHS-R1a was frequently detected in tumor cells and in proliferating 
microvessels of GBs and AAs, but little expression of ghrelin/GHS-R1a was 
detected in DAs. The frequency of ghrelin expression was almost the same in GBs 
and AAs (38/39, 97% and 12/13, 92%, respectively), but that of GHS-R1a 
expression was clearly different (39/39, 100% and 5/13, 38%, respectively). With 
regard to  proliferative activity, GBs, AAs, and DAs showed MIB-1 labeling 
indices ranging from 4 to 56 (mean: 22.3+12.9),  5 to 40 (mean: 15.9+14.0), and 1 
to 7 (mean: 2.2+1.8), respectively (Table 1). Fluorescent double immunostaining 
of ghrelin and the GHS-R1a in GB tissue confirmed positive staining of ghrelin 
and the GHS-R1a in the same tumor cells (Fig. 3a-3d). In addition, fluorescent 
double immunostaining of endoglin (CD105) and GHS-R1a confirmed positive 
staining of endoglin (CD105) and GHS-R1a in the same endothelial cells of 
proliferating microvessels (Fig. 3e-3f). On the other hand, fluorescent double 
immunostaining of GHS-R1a and Ki-67 in GB tissue did not confirm positive 
staining of the GHS-R1a and Ki-67 in the same tumor cells (Fig. 3i-3l). 
To gain a better understanding of the relationship between the 
ghrelin/GHS-R1a axis and the prognosis of patients with astrocytic tumors, 
statistical analyses were performed. Univariate analysis of overall survival 
indicated that, when ghrelin was used a marker, there was no significant difference 
in the survival rate between any of the three ghrelin groups (A: no staining and 1+, 
B: 2+, C: 3+, p=0.2310 for all comparisons) (Fig. 4a).  In contrast, when GHS-R1a 
was used a marker, there was a significant difference in the survival rate between 
all three ghrelin groups (A: no staining and 1+, B: 2+, C: 3+, p=0.0080 for all 
comparisons) (Fig. 4b).  
Considering age and ghrelin/GHS-R expression,  patients were classified into 
lower-score, moderate, and high-score ghrelin/GHS-R categories or lower-score, 
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and high-score ghrelin/GHS-R categories according to principal component 
analysis and cluster analysis. Multivariate analysis of overall survival indicated 
that there was a significant difference between the lower score groups (B) and the 
high grade score groups (A) or between the moderate score groups (C) and the 
high grade score groups (A), for each comparison (p=0.0005) (Fig. 4c). In addition, 
there was a significant difference in overall survival between the lower to 
moderate-score group (B) and the high-score group (A) (p=0.0001) (Fig. 4d).  
Correlation between Ghrelin/ GHSR-1a expression and the MIB-1 labelling 
index in gliomas was investigated using the Kendall tau rank correlation test. 
There was no significant correlation between either Ghrelin or GHSR-1a 
expression and the MIB-1 labelling index in gliomas (Table 3).  
 
DISCUSSION 
Many studies of the ghrelin/GHS-R signaling system have been carried out, 
primarily in the field of the regulation of appetite and gut motility, growth 
hormone release from the anterior pituitary, and its roles in the cardiovascular and 
immune systems. 1-4 In the central nervous system, ghrelin has been found in the 
hypothalamic arcuate nucleus, an important region for controlling appetite. In 
addition, the presence of ghrelin has been reported in hypothalamic neurons 
adjacent to the third ventricle between the dorsal, ventral, paraventricular, and 
arcuate hypothalamic nuclei, where it plays a role in controlling food intake.1-4 
Furthermore, several other functions of ghrelin such as stimulation of 
neurogenesis18 and inhibition of oligodendrocytic cell death in the central nervous 
system have been reported. 19 
Recent investigations have shown that ghrelin and the GHS-R may also play 
an important autocrine/paracrine role in many of various neoplasms. 5-14 For 
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example, in the human gastric cell line, Tian et al. have shown that ghrelin 
signaling promotes expression of the CDK6 oncogene and represses expression of 
the tumor suppressor gene p53. In addition, they reported that ghrelin activates 
expression of the metastasis factor MMP2 in gastric cancer cells via a 
GHS-R/NF-κB signaling pathway and promotes the proliferation of tumor cells. 10 
In an immunohistochemical study, Omoto et al. showed that ghrelin expression 
correlated with tumor depth and tumor differentiation, suggesting an important 
role for ghrelin in tumor growth in esophageal carcinoma. 11  Interestingly, Lin et al. 
reported that ghrelin could activate Snail, a transcriptional repressor of E-cadherin 
via the GHS-R-P13K-Akt axis, which might contribute to renal cell carcinoma 
metastasis. 12 
On the other hand, some reports have indicated that ghrelin inhibits the 
proliferation of tumor cells. 20,21 Thus, Rotondo et al. reported that ghrelin 
immunopositivity did not serve as a biomarker of biologic behavior, prognosis, or 
therapeutic responsiveness in pituitary adenoma.20 Xu et al. reported that ghrelin 
inhibited ovarian epithelial carcinoma in vitro.21  The structure of ghrelin is unique 
in that specific acyl-modification of its third serine is necessary for ghrelin to bind 
to GHS-R1a and exert biologic activity. The enzyme responsible for acylation of 
ghrelin is highly expressed in the stomach, lung, pituitary, adrenal cortex, and 
spleen, but is very weakly expressed in the ovary. Therefore, regarding the 
discrepancy in the function of ghrelin/GHS-R1a between other cancers and 
ovarian cancers, Xu et al. speculated that the effect of active acyl ghrelin on 
ovarian carcinoma might still occur through an endocrine rather than a 
paracrine/autocrine pathway. 
The role of the ghrelin/GHS-R axis in the development of gliomas has not been 
investigated in detail. In the present study, we detected ghrelin/GHS-R1a 
expression by various astrocytic tumor cells using immunohistochemistry. 
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However, although strong expression of ghrelin/GHS-R1a was frequently 
detected in tumor cells and proliferating microvessels of GBs and AAs, little 
expression of ghrelin/GHS-R1a was detected in DAs. The rate of ghrelin 
expression was almost the same in GBs and AAs (38/39, 97% and 12/13, 92%, 
respectively), but the rate of GHS-R1a expression was clearly different (39/39, 
100% and 5/13, 38%, respectively). These combined results indicated that the 
ghrelin/GHS-R1a axis plays an important role in the tumorigenesis of high grade 
gliomas, particularly of GBs. These data also suggest that ghrelin/GHS-R1a 
signaling is not as effective in AAs compared with GBs. GBs are characterized by 
pseudopalisade necrosis and increased levels of angiogenesis. These features are 
pathophysiologically linked and mechanistically instrumental to disease 
progression. Recent investigations have shown that the initial events of 
pseudopalisade formation in GBs are as follows.22,23  First, vascular occlusion 
related to endothelial apoptosis and intravascular thrombosis leads to ischemia and 
subsequently to hypoxia in the region around the vessels. Secondly, 
hypoxic-induced tumor cells begin to move away from the hypoxic zone, creating 
a peripherally moving wave of cells and forming a pseudopalisade with central 
necrosis. Third, a strong angiogenic response results in microvascular formation in 
regions peripheral to the central necrosis. Interestingly, in the present study, the 
percentage of tumor cells that expressed ghrelin and the GHS-R correlated with 
the WHO grade of gliomas. In addition, GBs showed moderate to intense 
immunostaining of both ghrelin and GHS-R1a, with immunostaining being 
particularly observed in the pseudopalisading cells and in CD-105 labeled 
proliferating microvessels. 
Angiogenesis is the process by which tumors induce a blood supply, and it 
plays a crucial role in both tumor growth and tumor progression. 24,25 Endoglin 
(CD105) is predominantly expressed on cellular lineages within the vascular 
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system. Endoglin (CD105) is overexpressed by proliferating endothelial cells that 
participate in tumor angiogenesis, whereas it is either weakly or not expressed in 
the vascular endothelium of normal tissues. Yao et al. have shown that endoglin 
(CD105) is a more specific and sensitive marker of microvessels in astrocytic 
tumors than other commonly used pan-endothelial antibodies. 25 Milewski et al. 
have recently shown that ghrelin/GHS-R1a are expressed both in glandular 
endometrioid epithelium and in some stromal cells, particularly in some 
fibroblasts, blood vessels, and infiltrating leukocytes in ovarian endometrioma. 26 
Based on their results, they speculated that co-localization of ghrelin/GHS-R1a 
affects the development and growth of endometriotic lesions and influences local 
inflammatory and angiogenic responses. In the present study, we also detected 
high expression of ghrelin/GHS-R1a in tumor cells and proliferating microvessels 
of AAs and GBs. We also found that GHS-R1a co-localized with endoglin (CD 
105) in proliferating microvessels. These data therefore suggest that 
ghrelin/GHS-R1a interactions play an important role in growth, invasion, and 
neoangiogenesis in high grade astrocytic tumors through both autocrine and 
paracrine mechanisms. 
Hirano et al. suggested that insulin-like growth factor-1 (IGF-1) signaling 
occurs early in astroglial tumorigenesis in the setting of cell proliferation. They 
further suggested that the distinctive correlative patterns of IGF-1 and insulin-like 
growth factor-1 receptor (IGF-1 R) signaling have an association with the 
development of malignant phenotypes related to aberrant angiogenesis and 
invasive tumor interactions with reactive brain. 27 Many tumors are responsive to 
the mitogenic influence of components of the growth hormone (GH) axis. There is 
increasing evidence that GH contributes both directly and indirectly (via its tissue 
biomediator, IGF-1) to neoplastic tissue growth. Ghrelin is known to enhance the 
GH/IGF axis via activation of the GHS-R, resulting in increased GH and IGF-1 
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production. 8  These findings therefore suggested that ghrelin plays an important 
role in growth, invasion, and neoangiogenesis in high grade astrocytic tumors via 
activation of the GH/IGF axis.  
Dixit et al. demonstrated that ligation of the GHS-R on cells of an astrocytoma 
cell line by ghrelin resulted in an increase in intracellular calcium mobilization, 
protein kinase C activation, actin polymerization, matrix metalloproteinase-2 
activity, and astrocytoma motility. In addition, their analysis of a central nervous 
system tumor tissue microarray showed that strong GHS-R and ghrelin expression 
was significantly more common in high grade tumors compared with low grade 
tumors.13 Based on these results, they considered that the ghrelin/GHS-R axis 
plays a role in astrocytoma cell migration and invasiveness. Chen et al. have 
shown that ghrelin increases GHS-R up-regulation, and that the enhancement of 
ghrelin-induced glioma cell motility is markedly inhibited by a GHS-R antagonist 
in vitro. 14 They therefore suggested that ghrelin-enhanced migration of glioma 
cells is mainly regulated by a GHS-R, CaMKII, AMPK, and NF-κB pathway.  
In the present study, there was no significant correlation between either ghrelin 
or GHSR-1a expression and the MIB-1 labelling index in gliomas. In addition, 
fluorescent double immunostaining of GHS-R1a and Ki-67 in GB tissue did not 
confirm positive staining of the GHS-R1a and Ki-67 in the same tumor cells. 
Ki-67 is an antigen that corresponds to a nuclear nonhistone protein expressed by 
cells in the cell cycle proliferative phases of G1, G2, M, and S.28  In addition, a 
monoclonal antibody (MIB-1) recognizes a formalin-resistant epitope of Ki-67. 28   
Therefore, these results indicated two possibilities regarding the role of Ghrelin/ 
GHS-R in the tumorigenesis of gliomas, in particular in GBs. First, upon 
stimulation of Ghrelin/ GHS-R signaling from quiescent tumor cells themselves, 
the quiescent tumor cells (in G0) might enter G1, after they progress to cell 
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division. Second, Ghrelin/ GHS-R might play an important role in the migration 
and invasiveness of tumor cells rather than in the proliferation of tumor cells. 
We also showed that the survival rate of patients with tumors that showed 
lower-expression of ghrelin/GHS-R was significantly higher than that for patients 
with tumors that showed higher-expression of ghrelin/GHS-R. In addition, in 
multivariate analysis, the ghrelin/GHS-R1a axis emerged as an independent 
prognostic factor in glioma patients. We thus considered that interactions of 
ghrelin/GHS-R are necessary for the growth of high-grade astrocytic tumors, 
particularly of GBs.  
In conclusion, the high expression of the ghrelin/GHS-R axis by GB cells and 
endothelial cells of proliferating microvessels that was determined in the present 
study may indicate an interaction between tumor cells and the tumor 
microenvironment, which could explain the pathological processes of GBs. In 
addition, the ghrelin/GHS-R pathway may be regarded as a potential therapeutic 
target for various cancers. The present study could thus eventually lead to 
therapeutic trials of treatments for patients with GBs in the future. 
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Figure Legends 
 
Figure 1  
Representative immunohistochemical staining of ghrelin and GHS-R1a in 
glioblastoma.  
a. Strong immunostaining of ghrelin in the pseudopalisading cells is shown 
(asterisk, necrosis; bar =20 m). 
b. Strong immunostaining of ghrelin in glioblastoma cells and in endothelial cells of 
proliferating microvessels (arrows) is shown. (bar =20 m). 
c. Strong immunostaining of GHS-R1a in the pseudopalisading cells is shown 
(asterisk, necrosis; bar =20 m). 
d. Strong immunostaining of GHS-R1a in glioblastoma cells and in endothelial cells of 
proliferating microvessels (arrows) is shown. bar =20 m). 
 
Figure 2 
Representative immunohistochemical staining of ghrelin and GHS-R1a in 
anaplastic astrocytomas and in diffuse astrocytoma tissues. 
a. Strong immunostaining of ghrelin in anaplastic astrocytoma cells and endothelial 
cells of proliferating microvessels (arrow) is shown. (bar =20 m). 
b. Strong immunostaining of GHS-R1a in anaplastic astrocytoma cells and in 
endothelial cells of proliferating microvessels (arrow) is shown. (bar =20 m). 
c. Weak immunostaining of ghrelin in diffuse astrocytoma cells is shown. No 
staining is seen in endothelial cells of proliferating microvessels (arrow; bar 
=20 m). 
d. No immunostaining of GHS-R1a of diffuse astrocytoma cells and endothelial cells of 
proliferating microvessels (arrow) was observed (bar =20 m). 
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Figure 3   
Representative double immunofluorescent staining of GHS-R1a and ghrelin or endoglin 
(CD105) in glioblastoma (a-d). Ghrelin (green, Alexa488) and GHS-R1a (red, Texas 
Red) were co-stained in glioblastoma tissue and detected by immunofluorescence. Tumor 
cells showed co-staining of GHS-R1a and ghrelin. a. ghrelin, b. GHS-R1a, c. DAPI, d. 
Merged (bar=10 m). 
 
e-h. Representative double immunofluorescent staining of endoglin (CD105; green, 
Alexa488) and GHS-R1a (red, Texas Red) in glioblastoma tissue. Vascular endothelial 
cells were co-stained for CD105 and GHS-R1a. e. endoglin (CD105), f. GHS-R1a, g. 
DAPI, h. Merged (bar=10 m). 
 
i-l. Representative double immunofluorescent staining of Ki-67 (MIB-1; green, 
Alexa488)  and GHS-R1a (red, Texas Red) in glioblastoma tissue did not confirm 
positive staining of  Ki-67 and the GHS-R1a in the same tumor cells. i. Ki-67, j. 
GHS-R1a, k. DAPI, l. Merged (bar=10 m). 
 
Figure 4  
Univariate and multivariate analysis of overall survival according to ghrelin and 
GHS-R1a expression. 
(a, b) Univariate analysis of overall survival curves (Kaplan-Meier). 
a. When ghrelin was used a marker, there was no significant difference in the 
survival rate between any of the three ghrelin groups (A: no staining and 1+, B: 
2+, C: 3+, p=0.2310 for all comparisons) 
b. When GHS-R1a was used a marker, there was significant difference in the 
survival rate between any of the three ghrelin groups (A: no staining and 1+, B: 
2+, C: 3+, p=0.0080 for all comparisons) 
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(c, d) Multivariate analysis of overall survival of overall survival curves 
(Kaplan-Meier). 
c. There was a significant difference between the low score groups (B) and high 
grade score groups (A) and between the moderate score groups (C) and high 
grade score groups (A) (p=0.0005 for each comparison). 
d. There was a significant difference in overall survival between the lower to 
moderate -score group (B) and the high-score group (A) (p=0.0001) 
 







Table 1. Clinicopathological characteristics of patients 
 
Factor Number 
Gender 
  Male 
  Female 
 
                 35  
                 28          
Histological type 
Glioblastoma 
Anaplastic astrocytoma  
Diffuse astrocytoma 
 
                 39 
                 13 
                 11 
MIB-1 labelling index 
Glioblastoma 
Anaplastic astrocytoma  
Diffuse astrocytoma 
            The range (the mean)  
4 to 56 (22.3+12.9) 
5 to 40 (15.9+14.0) 
1 to 7 (2.2+1.8) 
Age (yr) 
Glioblastoma 
Anaplastic astrocytoma  
Diffuse astrocytoma 
       The range (11 to 83)  
60.8+12.8 
52.7+18.2 
34.4+25.2 
Tumor location 
Glioblastoma 
Anaplastic astrocytoma  
Diffuse astrocytoma 
 
FR:lt.5,rt.9;TEM:lt.6,rt.8;PA:lt.3,rt.2;OC:lt.1, rt.3;CER:2 
FR:lt.5,rt.3;TEM:rt.1;PA:rt.2; TH: lt.1,rt.1 
FR:lt.3,rt.2;TEM:lt.3,rt.2; TH: lt.1 
FR, frontal;TEM, temporal;PA, parietal;OC, occipital;TH, thalamus;CER, cerebellum; lt, left;rt, right 
Table 2. Proportion of ghrelin/GHSR-1a-expressing cells by histopathological type of gliomas 
 
Factor Ghrelin GHSR-1a 
(-)    1+    2+    3+    (-)    1+    2+    3+ 
Glioblastoma (n=39) 1     0     9    29 0     0    13    26 
Anaplastic astrocytoma (n=13) 1     0     3     9 9     0     2     3 
Diffuse astrocytoma (n=11) 9     1     1     0 10     1     0     0 
(-), no staining; 1+, 0-10% positive cells; 2+, 10-50% positive cells; 3+, > 50% positive cells 
Table 3. Correlation between Ghrelin/GHSR-1a expression and MIB-1 labelling index in gliomas 
 
Variables Coefficient of correlation P value 
Ghrelin    vs.  MIB-1 -0.2343 0.1139 
GHSR-1a  vs.  MIB-1 -0.1019 0.5013 
(Kendall tau rank correlation test) 
 
 
 
 
